Q-omics provides the consensus-scored AKT2 profile across patient tissues and cancer cell-line models. AKT2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, AKT2 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, AKT2 RNA expression shows 20,049 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where AKT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKT2 survival associations across molecular data types. AKT2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKT2 RNA expression–survival associations across cancer types. High AKT2 expression shows unfavorable associations in ACC, UCEC and LGG, but favorable associations in BRCA, UCS and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for AKT2 RNA expression.
This table summarizes AKT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for AKT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKT2 shows lower tumor expression in THCA and KIRC and higher tumor expression in COAD, LUAD, CHOL and LUSC. The THCA box plot shows higher AKT2 RNA expression in normal versus tumor tissue (log2 FC = −1.235, t-test p < 0.001).
This table shows molecular features associated with AKT2 in patient tissues and cancer cell lines. In patient samples, AKT2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, AKT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
